BeyondSpring Inc. Ordinary Shares
BYSIBeyondSpring Inc. is a global pharmaceutical company focused on developing innovative therapies to improve patient outcomes in oncology, infection, and inflammation. Founded with an emphasis on novel small-molecule treatments, the company aims to bring new immuno-oncology and infectious disease solutions to the market.
Company News
BeyondSpring presented Phase 3 DUBLIN-3 trial results showing Plinabulin plus docetaxel improved overall survival in Asian patients with EGFR wild-type non-small cell lung cancer, with reduced neutropenia and promising survival rates.
SEED Therapeutics received FDA designations for its lead oncology asset ST-01156, a molecular glue that degrades RBM39. The company also announced strategic transactions with its largest shareholder, BeyondSpring, to diversify its shareholder base.
BeyondSpring announced the sale of a portion of its equity interest in SEED Therapeutics for $35.4 million. The proceeds will be used to advance the late-stage clinical trials of BeyondSpring's lead asset, Plinabulin, a first-in-class anti-cancer agent.
BeyondSpring presented updated results from a phase 2 study evaluating a triple combination of pembrolizumab, plinabulin, and docetaxel in metastatic NSCLC patients who progressed on prior immune checkpoint inhibitors. The regimen showed promising efficacy with a disease control rate of 89.3% and median PFS of 8.6 months.
BeyondSpring's plinabulin/docetaxel combination demonstrated significant improvements in overall survival, progression-free survival, and objective response rate compared to docetaxel alone, with an 80% reduction in grade 4 neutropenia and improved patient quality of life.
